This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Pillar Patient Advocates is working with a research firm who is looking to include 30 patient and 10 caregivers in a 60 minute phone/web interview to review materials in development. To be considered, participants should have experience with Imbruvica (Ibrutinib) or Calquence (acalabrutinib) and received initial diagnosis within the last 10 years. In appreciation, participants are compensated $150 for their time and input. If interested in participating, please email Erin Pilkington at Epilkington@PillarAdvocates.com and provide a phone number that you can be reached at to go through a few screening questions for qualification.
Please let the CLL Society know if you are chosen to participate by emailing support@cllsociety.org with “Participating in the Pillar Interview” in the subject line. Thank you! The details of the interview are fully independent on the CLL Society and our announcement of this opportunity should not be construed as an endorsement.